Abstract: Objective To compare the clinical efficacy and safety of interferon α-2b combined with adefovir dipivoxil or entecavir in the treatment of drug-resistant e-antigen positive hepatitis B. Methods 86 patients with drug-resistant e-antigen positive hepatitis B were admitted from the First Affiliated Hospital of Xinjiang Medical University from October 2016 to January 2018. The patients were divided into two groups by random number table. The patients treated with interferonα-2b combined with adefovir dipivoxil were divided into group A and those treated with interferonα-2b combined with entecavir were divided into group B. After 24, 48 weeks of treatment and 24 weeks of follow-up, the therapeutic responses (virological and biochemical responses), serological indicators (HBeAg seroconversion and negative HBeAg, HBsAg and HBV DNA) and drug safety were compared between the two groups. Results After 24, 48 weeks of treatment and 24 weeks of follow-up, the serological conversion of HBAg in group B was better than that in group A (P < 0.05). The treatment response, HBeAg negative, HBsAg negative, HBV DNA negative and adverse reactions during treatment in the two groups have no significant (P > 0.05). Conclusion Interferonα-2b combined with adefovir dipivoxil or entecavir is effective in the treatment of drug-resistant hepatitis B with e antigen positive. Among them, the combination therapy of entecavir can significantly improve the serological conversion of HBeAg in patients with higher application value.

Key words: interferonα-2b, adefovir dipivoxil, entecavir, drug-resistant e antigen positive, hepatitis B